Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

The FDA removes the partial clinical holds on Rezolute's phase III study evaluating RZ358 for treating congenital hyperinsulinism.

The phase III THRIVE study evaluating Viridian's veligrotug for treating active thyroid eye disease meets all primary and secondary endpoints.

Ocugen, Inc., a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, announced...

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

BIIB's pivotal mid to late-stage study evaluating a higher dosing regimen for Spinraza to treat SMA in infants meets the primary and secondary goals.

Dimerix has enrolled the first patient into the Open Label Extension study for its kidney disease drug candidate DMX-200 after ...

A new study suggests that depression in some people might be linked to the same toxic plaques in the brain that are associated with Alzheimer’s...